News

Fierce Pharma23h
With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs
In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...
PipelineReview.com23h
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China’s NMPA for Chronic Weight Management
SAN FRANCISCO, CA, USA and SUZHOU, China I June 27, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical ...